0      0

JL1107EH - JL1107EH: Ibrutinib Dose Modifications for Management of Cardiac Adverse Events in Patients with B-cell Malignancies: Pooled Analysis of 10 Clinical Trials

Full author listing

Deborah M. Stephens, DO,1 Jennifer R. Brown, MD, PhD,2 Shuo Ma, MD, PhD,3 Michael Wang, MD,4 Carol Moreno, MD, PhD,5 Tadeusz Robak, MD, PhD,6 Don A. Stevens, MD,7 Shane Lee,8 Chadi Saifan,8 Emily Hsu, PhD,8 Sima Patel, PhD8 Jan A. Burger, MD, PhD9

1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 2CLL Center, Dana-Farber Cancer Institute, Boston, MA, USA; 3Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 4University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain; 6Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; 7Norton Cancer Institute, Louisville, KY, USA; 8Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, USA; 9Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.


You must be logged in and own this session in order to post comments.